KKR Buys Pfizer’s Capsugel
Private equity firm KKR will buy Pfizer’s Capsugel business for $2.375 billion in cash, the firms revealed Monday morning in a joint statement. Capsugel generated about $750 million in revenue in 2010, the statement revealed. Pfizer’s financial advisors for the transaction were Morgan Stanley & Co. Incorporated and Guggenheim Securities, LLC. Cadwalader, Wickersham & Taft LLP and White & Case LLP acted as legal counsel for Pfizer. Simpson Thacher & Bartlett LLP acted as legal counsel for KKR.
4 April 2011•5 mins read
